AI Article Synopsis
- New diagnostic techniques are transforming how pathologists diagnose thyroid cancers by combining genetic and molecular data.
- The V600E mutation and specific markers like HBME-1 and galectin-3 are notably associated with papillary thyroid carcinoma (PTC).
- The study aims to investigate the relationship between V600E mutation and the expression of HBME-1 and galectin-3 in thyroid tumors, assessing their effectiveness as diagnostic tools.
Article Abstract
Newer diagnostic modalities have revolutionized the pathologist's approach to diagnosing thyroid malignancies. Molecular characterization of these malignancies has helped circumvent common morphologic diagnostic difficulties by integrating their genotypic, phenotypic, and immunohistochemical features. V600E mutation has been characterized as highly specific for thyroid carcinoma, especially papillary thyroid carcinoma (PTC); human bone marrow endothelial marker-1 (HBME-1) and galectin-3 are also such markers that are highly specific for PTC. We propose to study HBME-1 and galectin-3 expression and V600E mutation in thyroid neoplasms and do a comparative analysis to determine whether there is a correlation between V600E expression and that of HBME-1 and galectin-3. We further propose to analyze the individual and combined diagnosed utility of the above-mentioned ancillary diagnostic techniques.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668044 | PMC |
| http://dx.doi.org/10.7759/cureus.20339 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!